A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
The Oxford Respiratory Trials Unit (ORTU) at the Nuffield Department of Medicine has been awarded a \u00a32.8 million grant from the National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) to conduct the MIST4 study.
The efficacy of artemisinin derivatives, the cornerstone of current treatments for malaria, is being compromised in Africa where over 1,000 children are estimated to die each day from the disease. The spread of artemisinin-resistant malaria parasites across East Africa and beyond could result in millions more deaths without immediate health policy changes, warn experts in a paper published in Science.
A recent publication by OUCRU researchers, published in the journal Public Health Action, highlights the importance of community engagement in TB research.
Oxford immunologists Professor Omer Dushek and Professor Anton van der Merwe have founded a new company called MatchBio, which aims to apply a range of approaches to make CAR T therapy more effective.
Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford.
Today marks the official rollout of the new R21/Matrix-M\u2122 malaria vaccine - co-developed by the University of Oxford and Serum Institute of India, leveraging Novavax\u2019s Matrix-M\u2122 adjuvant technology. In a historic step in the battle to beat malaria, the first official vaccination is due to take place in Abidjan, C\u00f4te d\u2019Ivoire, this morning and will be subsequently rolled-out in 38 districts across the country.
A new study has used state-of-the-art single cell multiomic techniques to discover a novel population of immune cells that mediate a substantial proportion of the genetic risk of heart disease. The characteristics of these cells make them potential targets for new treatments.
Research has unveiled the intricate cellular landscape of healthy human hamstring tendons, shedding new light on this vital yet often overlooked component of our musculoskeletal system.
A new study published by Oxford researchers as part of an international collaboration in the Journal of Biological Chemistry has found that an important section of our immune system, that involves the molecule MR1 and MAIT cells, is evolutionarily conserved in multiple species.
Sepsis patients could be treated based on their immune system\u2019s response to infection, not their symptoms. New research uncovers how different people respond to sepsis based on their genetic makeup, which could help identify who would benefit from certain treatments and lead to the development of targeted therapies.
Thanks for the Memories, Wellcome-funded public engagement project led by Prof. Paul Klenerman and composer Dr Zakiya Leeming, hosted an innovative evening of music and science at the Tingewick Hall, John Radcliffe Hospital, on 5th June.
Early results of an international study examining the risk of arthritis for people with psoriasis have shown a high burden of joint symptoms in 712 patients \u2013 25% of the total studied so far.
New research published by scientists at the University of Oxford, the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa, and the Ragon Institute of Mass General, MIT and Harvard, USA, shows that male infants are more likely to achieve HIV cure/remission than females.
Running continuously since Sept 2021, the PLATCOV trial at NDM's Mahidol Oxford Tropical Medicine Research Unit has randomised over 1700 patients presenting with COVID-19 infections. Work by PLATCOV\u2019s Dr Phrutsamon Wongnak published in the Lancet Infectious Diseases has shown that rates of oropharyngeal viral clearance have accelerated dramatically since the trial started: A SARS CoV2 viral clearance half-life in untreated patients of around 16 hours In Sept 2021 had reduced to around 9 hours by Oct 2023. The results highlight the importance of pharmacometric platform trials like PLATCOV, so that we are prepared for the next pandemic.
The Oxford Microbiome Network (OMiN) aims to facilitate collaborations, knowledge sharing, and access to resources for microbiome researchers across Oxford. OMiN is co-led by researchers in the Kennedy Institute of Rheumatology and the Department of Biology. The network officially launched on 20th May 2024 with an event at Keble College.
Thanks for the Memories, Wellcome-funded public engagement project led by Prof. Paul Klenerman and composer Dr Zakiya Leeming, hosted an innovative evening of music and science at the Royal Northern College of Music in early May.
![\"\"](\"https://www.immunology.ox.ac.uk/news/new-research-identifies-autoimmunity-against-a-key-anti-inflammatory-regulator/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n